Method and device for the detection of microsleep events

Details for Australian Patent Application No. 2009253692 (hide)

Owner Effective Control Transport, Inc.

Inventors Farbos, Bruno

Agent Spruson & Ferguson

Pub. Number AU-A-2009253692

PCT Pub. Number WO2009/143620

Priority 12/340,017 19.12.08 US; 61/071,966 28.05.08 US

Filing date 27 May 2009

Wipo publication date 3 December 2009

International Classifications

A61B 3/10 (2006.01) Apparatus for testing the eyes - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

A61B 5/00 (2006.01) Measuring for diagnostic purposes

A61B 5/0476 (2006.01) Measuring for diagnostic purposes - Electroencephalography

A61B 5/0496 (2006.01) Measuring for diagnostic purposes - Electro-oculography, e.g. detecting nystagmus

B60K 28/06 (2006.01) Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions

G08B 21/06 (2006.01) Alarms responsive to a single specified undesired or abnormal condition and not otherwise provided for

Event Publications

9 December 2010 PCT application entered the National Phase

  PCT publication WO2009/143620 Priority application(s): WO2009/143620

30 June 2011 Assignment before Grant

  Effective Control Transport, Inc. The application has been assigned to 7352867 Canada Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009253696-Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling

2009253683-Abrogating proinflammatory cytokine production during oncolytic reovirus therapy